Diagnexia and Stratipath Partner to Expand AI-Based Cancer Precision Diagnostics Across the UK and Europe
Diagnexia, and Stratipath AB are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.
Professor Daniel Hayes Joins Stratipath’s Scientific Advisory Board
Stratipath is proud to announce that globally recognized breast oncologist, Professor Daniel F. Hayes, has joined the company’s Scientific Advisory Board. Professor Hayes will collaborate closely with the board, chaired by Professor Jonas Bergh, to further advance Stratipath’s innovative solutions in breast cancer precision diagnostics.
Validation study including over 2,700 patients confirms the prognostic performance of Stratipath Breast
The study, which was recently published in Breast Cancer Research and conducted by Karolinska Institutet in Stockholm, validates the prognostic performance of Stratipath Breast in a large retrospective cohort of over 2,700 patients from two independent clinical sites.
Stratipath Secures Spot on Prestigious 33-List of Top Innovative Tech Companies for Third Consecutive Year
Stratipath has been recognized as one of the Gold Companies on NyTeknik – First with news about technology and IT. and Affärsvärlden’s prestigious 33-list – for the maximum three consecutive years!
Stratipath breast is demonstrating considerable agreement with established gene expression test
The findings showed that the Stratipath Breast analysis identified 49.6% of the clinically intermediate tumors as low risk and 50.4% as high risk. The Prosigna assay classified 32.5%, 47.0% and 20.5% tumors as low, intermediate and high risk, respectively. Among Prosigna intermediate-risk tumors, 47.3% were stratified as Stratipath low risk and 52.7% as high risk. In addition, 89.7% of Stratipath low-risk cases were classified as Prosigna low/intermediate risk. The overall agreement between the two tests for low-risk and high-risk groups (N = 124) was 71.0%, with a Cohen’s kappa of 0.42. For both risk profiling tests, grade and Ki67 differed significantly between risk groups.
Unilabs is implementing Stratipath Breast for enhanced breast cancer diagnostics at Capio S:t Göran’s Hospital
Capio St Göran’s Hospital is one of the largest breast cancer clinics in Sweden treating more than 600 breast cancer patients annually. With this new collaboration, Unilabs will use Stratipath Breast on a selected group of these patients.
High-Impact research in Annals of Oncology lays critical foundation for Stratipath Breast’s AI-based cancer diagnostics
This published high-impact scientific article from Karolinska Institutet shows that AI-supported image analysis can stratify intermediate-grade breast cancers into low or high risk categories This has strong prognostic value and potential to revolutionise breast pathology.
Article in ”Oncology in Sweden” on the continuation of SwAIPP (Sweden AI Precision Pathology)
SwAIPP 2, the continuation of the SwAIPP project, has been funded by Sweden’s innovation agency, Vinnova. We at Stratipath are proud to be partners in this consortium alongside leaders in academia, healthcare, and industry.
Podcast: “Precision Medicine is the Future of Healthcare – But Do We Have the Skills Needed?”
Johan Hartman is a guest at the Johnson & Johnson podcast “Vi forskar för livet” (“Research for Life”). The episode, titled “Precision Medicine is the Future of Healthcare – But Do We Have the Skills Needed?”
Article at Genomeweb: ”Stratipath Seeks to Ramp up Adoption of AI-Based Breast Cancer Test”
Johan Hartman is a guest at the Johnson & Johnson podcast “Vi forskar för livet” (“Research for Life”). The episode, titled “Precision Medicine is the Future of Healthcare – But Do We Have the Skills Needed?”